The synergistic inhibitory effect was stronger in the MACC1-overexpressing group than the MACC1 downregulated and their control groups (Fig. 6a), which indicated that MACC1 might be a prognosis factor for the combined use of trastuzumab and glycolysis inhibitors in HER2-positive GC. Here, MACC1 is linked to gastric cancer.